CJC-1295 Side Effects: Water Retention, Numbness, Glucose

CJC-1295 Side Effects: What the Evidence Actually Shows

CJC-1295 side effects include water retention, injection-site flushing, transient glucose shifts, and peripheral tingling from carpal-tunnel-like nerve compression. In Teichman et al. 2006, 60-90 mcg/kg doses were well tolerated in men aged 20-40, and most effects are dose-dependent, typically resolving within 7-28 days of dose reduction or discontinuation.

CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog that binds to albumin, extending its half-life to roughly 6-8 days and driving sustained pulsatile GH and IGF-1 secretion. In Teichman et al. 2006, a single injection produced dose-dependent GH increases of 2 to 10-fold lasting 6 or more days, and IGF-1 increases of 1.5 to 3-fold lasting 9 to 11 days, with no serious adverse reactions reported at the 30-60 mcg/kg range. A follow-up deep-phenotyping study, Ionescu and Frohman 2006, confirmed that CJC-1295 preserves the body's natural pulsatile GH release pattern even under continuous receptor stimulation, which is the mechanistic reason its side-effect profile looks different from a fixed daily HGH dose. That is the pharmacology working as intended. This guide covers what happens when GH and IGF-1 rise beyond baseline, whether that carries meaningful cancer or metabolic risk, and what to actually monitor.

Most readers here are running CJC-1295 for sleep and recovery or for longevity and IGF-1 maintenance. The side-effect profile is broadly the same across both use cases, but monitoring priorities shift depending on which one you're running.

How CJC-1295 Produces Its Side Effects: The Mechanism

Every side effect below traces back to the same two hormones: GH and IGF-1. CJC-1295 doesn't introduce a new mechanism of harm, it amplifies an existing physiological axis. GH is released from the anterior pituitary in pulses; IGF-1 is produced downstream, mostly in the liver, in response to those pulses. Water retention, tingling, and glucose shifts are all IGF-1-mediated or GH-mediated effects that show up at the tissue level once trough levels move above baseline for an extended stretch.

The key variable is dose and duration relative to your own physiological ceiling. Sigalos and Pastuszak 2018, a review of the growth hormone secretagogue class covering GHRH analogs and GH-releasing peptides, concluded that these compounds are generally well tolerated but flagged decreased insulin sensitivity and elevated blood glucose as a consistent signal across the class, alongside a call for more long-term data on cancer incidence with sustained use. That review is the single most useful anchor for framing everything that follows: mild, dose-dependent, and under-studied long-term, not dangerous by default.

Water Retention: The Most Common Side Effect

Water retention is the side effect users report most consistently with any GH-axis stimulation, and CJC-1295 is no exception. IGF-1 increases plasma renin activity and suppresses atrial natriuretic factor, the hormone responsible for sodium excretion. The net effect is sodium reabsorption in the kidneys followed by secondary water retention. This is a known class effect of GH-axis elevation, not something unique to CJC-1295, and it typically tracks with how far above your own baseline your trough GH and IGF-1 sit.

In most documented cases the fluid shift is transient and adapts within the first few weeks of continued use. Starting conservative rather than titrating up aggressively is the single biggest lever you have over how noticeable this side effect gets.

Practical signs to track

• Puffiness around the eyes or ankles on waking
• Ring or shoe tightness that wasn't there before
• Scale weight up 1-3 kg in the first two weeks with no dietary change
• Reduced visual definition despite no change in body fat

None of these alone confirm a problem, but tracking them against a personal baseline separates normal early-adaptation fluid shift from a genuine signal to drop your dose.

Numbness, Tingling, and Carpal Tunnel Risk

Peripheral tingling, most often in the hands and wrists, shows up with GH-axis elevation because IGF-1 drives soft-tissue proliferation. In the carpal tunnel specifically, that can mean increased synovial volume compressing the median nerve, which produces the classic pins-and-needles sensation and, in more pronounced cases, grip weakness. This is a recognized, dose-related effect across the GH secretagogue class rather than something specific to CJC-1295's chemistry.

Who carries more risk

• Anyone with pre-existing carpal tunnel symptoms
• Users titrating up quickly rather than starting conservative
• Anyone stacking CJC-1295 with a GHRP such as ipamorelin, which amplifies total GH pulse height
• Athletes doing high-volume grip or wrist-loading training

Tingling that starts in the first two to four weeks alongside grip weakness or nighttime wrist pain is a signal to drop dose immediately rather than wait it out. Early action shortens time to resolution considerably.

Glucose and Insulin: Can Diabetics or Insulin-Resistant Users Run This Safely?

GH is a counter-regulatory hormone for insulin. At high, fixed pharmacological doses it measurably reduces peripheral insulin sensitivity. The open question for CJC-1295 specifically is whether its more modest, pulsatile GH elevation carries the same risk, and the honest answer is: probably less, but not zero, and it depends heavily on your starting metabolic status.

Sigalos and Pastuszak 2018 identified decreased insulin sensitivity and elevated fasting glucose as a consistent adverse signal across the entire GH secretagogue class, GHRH analogs included, even though the mechanism (preserved pulsatility) is theoretically gentler than fixed-dose GH. That's the reason this section exists as a standalone rather than a footnote under water retention.

Practically: if you have type 2 diabetes, are insulin resistant, or have a strong family history of type 2 diabetes, CJC-1295 is not an automatic no, but it changes your monitoring obligations substantially.

Timing matters more than most protocols acknowledge. Injecting at night, fasted, away from a large carbohydrate load, aligns the GH pulse with the body's natural nocturnal GH rhythm and reduces the acute antagonism against insulin that happens when GH and a glucose load hit the bloodstream together. Uncontrolled type 2 diabetes, active gestational diabetes, or a recent hypoglycaemic event are reasons to avoid this compound entirely without direct clinical oversight.

IGF-1 and Cancer Risk: What the Evidence Actually Supports

This is the concern that stops people before they start, and it deserves a direct answer rather than a dodge. IGF-1 is mitogenic: it promotes cell growth and inhibits apoptosis, and epidemiological studies have linked chronically elevated IGF-1 to increased risk of several cancers, most consistently colorectal, breast, and prostate. A Mendelian randomization analysis of over 400,000 individuals, Larsson et al. 2020, found genetically predicted higher IGF-1 was associated with increased colorectal cancer risk specifically, with weaker or inconsistent signals for other cancer sites.

The critical distinction is physiological versus pharmacological IGF-1 exposure. Acromegaly, a condition of chronic, often decades-long, pathological GH/IGF-1 excess from a pituitary tumor, is the closest real-world model for what sustained supraphysiological IGF-1 actually does to cancer incidence over time. A 2025 prospective cohort of 598 acromegaly patients, Freda et al. 2025, found that cumulative exposure to IGF-1 excess, meaning the degree and duration of elevation, was a predictor of cancer risk, not any single measured IGF-1 level. A 2023 meta-analysis of acromegaly cohorts, Xiao et al. 2023, found increased risk for specific cancers including hematological, connective tissue, and pancreatic malignancies but no clear increased risk for prostate, hepatobiliary, or skin cancers, and mixed findings on breast cancer specifically.

What this means for a CJC-1295 protocol running weeks to months at GH-secretagogue doses: the IGF-1 elevation involved (roughly 1.5 to 3-fold above baseline per Teichman's dosing data) is meaningfully smaller in magnitude and duration than the decades-long pathological exposure seen in acromegaly. There is no direct clinical trial data on cancer incidence specifically from CJC-1295 use, because no long-term trial has run. That absence of data is not the same as a clean bill of health, and it's the reason a personal or family history of hormone-sensitive cancer (breast, prostate, colorectal) is one of the clearest contraindications for this compound rather than a discussion topic.

Injection-Site Reactions and Flushing

Subcutaneous injection can produce localised redness, warmth, and mild, self-limiting itching at the site. Facial flushing in the minutes after injection has also been reported, most likely reflecting an acute vasodilatory response to the peptide itself rather than the GH release. These reactions are low severity across the board and tend to diminish with continued use as local tissue desensitizes.

Dosing Protocol: What Actually Keeps Side Effects Manageable

The tactical rule that matters most: dose up slowly, hold longer than feels necessary, and treat any new symptom as a reason to step back rather than push through. CJC-1295's long half-life means a dose you inject Monday is still partially active through the weekend, so side effects don't clear quickly if you overshoot. That makes conservative titration a bigger lever here than with a shorter-acting peptide.

CJC-1295 vs Other GH-Axis Peptides: Side-Effect Comparison

Who Shouldn't Use CJC-1295

• Active cancer or a personal/family history of hormone-sensitive cancers (breast, prostate, colorectal) without oncologist clearance
• Uncontrolled type 2 diabetes or a recent hypoglycaemic event
• Untreated hypothyroidism, which blunts the GH axis response and can mask dosing feedback
• Pregnancy or breastfeeding; no reproductive safety data exists
• Anyone unwilling to run baseline and follow-up bloodwork (fasting glucose, IGF-1, HbA1c)

Common Mistakes That Make Side Effects Worse

• Titrating dose up in the first week instead of holding at a low starting dose for 2-4 weeks
• Injecting close to a large carbohydrate meal, which amplifies the acute glucose-insulin antagonism
• Stacking with a GHRP at full dose from day one instead of introducing one variable at a time
• Ignoring early tingling or grip weakness instead of treating it as an immediate dose-reduction signal
• Running continuously for months with no off period, increasing pituitary desensitization risk
• Sourcing from a vendor with no third-party testing; see how to know if peptides are real and how to read a peptide CoA before you buy

Sourcing and Verification

CJC-1295 is not FDA-approved for any indication, and it circulates in a research-compound gray market with far less oversight than an approved drug. That means product quality varies enormously between vendors, and a mislabelled or underdosed vial can produce a side-effect picture that has nothing to do with the pharmacology described above. Before you buy anything, check our recommended sources for vendors that provide third-party certificates of analysis, and read our guide on reliable peptide sources and how to reconstitute peptides correctly once you have a verified product in hand.

Regulatory Status

CJC-1295 has moved through several FDA regulatory postures over the past few years, and its status can shift again. It has never been FDA-approved as a drug for any indication, and the absence of a completed phase III trial program means rare, long-term adverse events (including any cancer signal) may not yet be fully characterized in the way they would be for an approved compound. Treat every dosing decision here as a research-use decision, not a treatment decision, and loop in a qualified clinician if you have any pre-existing condition on the contraindication list above.

Related Stack Options

If recovery rather than pure GH/IGF-1 elevation is the goal, several UB readers stack or substitute with tissue-repair peptides instead of, or alongside, CJC-1295. Our guides on the wolverine stack (BPC-157 and TB-500), TB-500's complete guide, and best peptides for injury recovery in 2026 cover recovery-focused alternatives with a different side-effect profile than sustained GH-axis stimulation.

This content is for educational purposes only. CJC-1295 and related peptides are intended for research use. Nothing in this article is medical advice, and any decision to start, stop, or adjust a protocol, especially with a pre-existing metabolic or oncologic history, should involve a qualified clinician. If you're researching this compound, our recommended sources are linked above and support ongoing independent testing and coverage.